Spotlight Commentary – Voxelotor: A new kid on the block in the treatment of sickle cell disease
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15249
Abstract: Sickle cell disease (SCD) is a common inherited disorder, which is caused by a mutation in the haemoglobin β subunit gene that results in the formation of sickle haemoglobin (HbS). On deoxygenation, HbS polymerizes, that… read more here.
Keywords: cell; pharmacology; voxelotor; sickle ... See more keywords
Association between hydroxycarbamide exposure and neurocognitive function in adolescents with sickle cell disease
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16519
Abstract: Patients with sickle cell disease (SCD) are at increased risk for neurocognitive impairments. While disease‐modifying treatment, such as hydroxycarbamide (hydroxyurea), may decrease this risk, it has not been systematically investigated in children with SCD. We… read more here.
Keywords: thalassaemia; hydroxycarbamide; hbs thalassaemia; hbsc hbs ... See more keywords
Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood-2017-05-785790
Abstract: Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis and leukemia. Patients resistant/intolerant to hydroxycarbamide (HC) have a poor outlook. MAJIC (ISRCTN61925716) is a… read more here.
Keywords: ruxolitinib; trial; best available; available therapy ... See more keywords
The poor outcome in high molecular risk, hydroxycarbamide resistant/intolerant ET is not ameliorated by ruxolitinib.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood.2019001861
Abstract: Essential Thrombocythemia (ET) patients at high-risk of thrombosis require cytoreductive treatment, typically with hydroxycarbamide. Many patients are resistant or intolerant to hydroxycarbamide (HC-RES/INT) and are at increased risk of disease progression. MAJIC-ET is a randomized… read more here.
Keywords: risk; hydroxycarbamide; res int; analysis ... See more keywords
A Microbiota-Dependent Response to Anticancer Treatment in an In Vitro Human Microbiota Model: A Pilot Study With Hydroxycarbamide and Daunorubicin
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cellular and Infection Microbiology"
DOI: 10.3389/fcimb.2022.886447
Abstract: Background Anticancer drug efficacy is linked to the gut microbiota’s composition, and there is a dire need to better understand these interactions for personalized medicine. In vitro microbiota models are promising tools for studies requiring… read more here.
Keywords: microbiota; hydroxycarbamide; human microbiota; model ... See more keywords